首页> 外文OA文献 >Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer

【2h】

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer

机译：评估局部确定的女性中局部和中央HER2测试之间的不间断率

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Peter A. Kaufman; Kenneth J. Bloom; Howard Burris; Julie R. Gralow; Musa Mayer; Mark Pegram; Hope S. Rugo; Sandra M. Swain; Denise A. Yardley; Miu Chau; Deepa Lalla; Bongin Yoo; Melissa G. Brammer; Charles L. Vogel;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer [J] . KaufmanP.A., BloomK.J., BurrisH., Cancer: A Journal of the American Cancer Society . 2014,第17期

机译：评估局部确定的HER2阴性乳腺癌女性的局部和中央HER2检测之间的不一致率
2. International, phase 3 trial: Balixafortide (a CXCR4 antagonist) plus eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) international, phase 3 trial: Balixafortide (a CXCR4 antagonist) plus eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：国际，第3阶段试验：Balixafortide（CXCR4拮抗剂）加二林蛋白与Eribulin单独服用Her2阴性，局部复发或转移性乳腺癌（堡垒）国际，第3阶段试验：Balixafortide（A CXCR4拮抗剂）加二林蛋白与二林林单独相反 HER2阴性，局部复发或转移性乳腺癌（堡垒）的患者
3. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort (vol 15, pg 640, 2014) [J] . Gianni L., Eiermann W., Semiglazov V The lancet oncology . 2018,第12期

机译：Neoadjuvant and Adduvant Trastuzumab在Her2阳性局部晚期乳腺癌患者（诺亚）：随机控制优势试验的随访，并行HER2阴性队列（Vol 15，PG 640,2014）
4. Automated cell segmentation and spot detection in fluorescence in situ hybridization staining to assess HER2 status in breast cancer [C] . Şükrü Burak Çetin, Fariba D. Khameneh, Ercan Alp Serteli, Signal Processing and Communications Applications Conference . 2018

机译：荧光原位杂交染色中的自动细胞分割和斑点检测，以评估乳腺癌中HER2的状态
5. Preclinical exploration of novel small molecules as anticancer agents in triple-negative and HER2/neu-positive breast cancers. [D] . Weng, Shu-Chuan. 2008

机译：在三阴性和HER2 / neu阳性乳腺癌中作为抗癌药的新型小分子的临床前探索。
6. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer [O] . Peter A Kaufman, Kenneth J Bloom, Howard Burris, -1

机译：评估局部确定的HER2阴性乳腺癌女性的局部和中央HER2检测之间的不一致率
7. Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First‐Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor‐Positive/HER2‐Negative Breast Cancer [O] . Beverly Moy, Patrick Neven, Fabienne Lebrun, 2014

机译：Bosutinib与芳香酶抑制剂Letrozole：绝经后妇女的II期试验评估局部晚期或转移激素受体阳性/ HER2阴性乳腺癌的一线内分泌治疗

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅